What's Happening?
Aptamer Group plc has launched a targeted radiopharmaceutical program in collaboration with Radiopharmium Ltd. This initiative aims to develop radioligand conjugates using the Optimer platform, which has demonstrated improved stability compared to existing
peptide-based approaches. The program targets three high-value clinical conditions and will progress through in vitro validation before advancing to in vivo studies. The Optimer-based radioligands showed only 8% degradation in tests, compared to 34-83% for peptide comparators, suggesting potential benefits in shelf life and logistics.
Why It's Important?
The development of more stable radiopharmaceuticals could revolutionize cancer imaging and therapy by reducing waste and simplifying logistics. Aptamer's Optimer platform offers a potentially differentiated profile that could enhance the effectiveness and accessibility of radiopharmaceutical treatments. This advancement may lead to improved patient outcomes and reduced healthcare costs, positioning Aptamer Group as a leader in the field of aptamer technology. The collaboration with Radiopharmium Ltd leverages expertise in radiopharmaceutical development, potentially accelerating the translation of these innovations into clinical practice.
What's Next?
The program will continue with in vitro validation and is expected to deliver in vivo data by the end of 2026. Aptamer Group plans to advance multiple assets towards clinical validation, potentially expanding its pipeline with additional radiotherapy assets. The collaboration aims to demonstrate the potential of aptamer-based targeting in next-generation radiopharmaceuticals, which could lead to new therapeutic options for patients with cancer and other diseases.
